Alnylam Pharmaceuticals, Inc. Expected to Earn Q2 2024 Earnings of ($0.90) Per Share (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities research analysts at Leerink Partnrs raised their Q2 2024 EPS estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Tuesday, June 25th. Leerink Partnrs analyst M. Foroohar now expects that the biopharmaceutical company will post earnings of ($0.90) per share for the quarter, up from their previous estimate of ($1.09). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($3.75) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q3 2024 earnings at ($0.91) EPS, Q4 2024 earnings at ($1.27) EPS, FY2024 earnings at ($3.61) EPS and FY2025 earnings at ($2.50) EPS.

Other equities research analysts also recently issued reports about the company. Citigroup lifted their price objective on Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a “buy” rating in a report on Tuesday. Canaccord Genuity Group reiterated a “buy” rating and issued a $283.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, June 21st. Barclays lifted their price objective on Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the company an “overweight” rating in a report on Tuesday. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a report on Monday. Eight equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $245.14.

Alnylam Pharmaceuticals Stock Up 0.7 %

NASDAQ ALNY opened at $247.00 on Friday. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $252.87. The stock has a market cap of $31.24 billion, a P/E ratio of -92.16 and a beta of 0.30. The company’s 50-day simple moving average is $157.89 and its 200 day simple moving average is $164.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same period in the previous year, the business posted ($1.40) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% compared to the same quarter last year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the sale, the executive vice president now directly owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the sale, the executive vice president now directly owns 14,181 shares in the company, valued at $3,275,669.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The disclosure for this sale can be found here. Insiders sold 67,357 shares of company stock valued at $13,436,711 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in ALNY. Allspring Global Investments Holdings LLC lifted its stake in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the last quarter. Quent Capital LLC lifted its stake in Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. Anchor Investment Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $38,000. Altitude Crest Partners Inc. bought a new position in Alnylam Pharmaceuticals during the first quarter worth about $30,000. Finally, GAMMA Investing LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.